SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2019
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
11099 N. Torrey Pines Road, Suite 190
La Jolla, California
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (858) 750-4789
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
|Common Stock, par value $0.001 per share||THOR||The Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|Item 8.01|| |
On September 30, 2019, certain members of the management team of Synthorx, Inc. (the Company) will be presenting a poster (the Poster) at the European Society for Medical Oncology Congress 2019 conference. A copy of the Poster is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
|Item 9.01|| |
Financial Statements and Exhibits.
|99.1||Poster, dated September 30, 2019.|
Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Words such as believe, may, will, estimate, promise, plan, continue, anticipate, intend, expect, potential and similar expressions (including the negative thereof) are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. For such statements, the Company claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from the Companys expectations. Factors that could cause actual results to differ materially from those stated or implied by the Companys forward-looking statements are disclosed in the Companys filings with the Securities and Exchange Commission, including in the section captioned Risk Factors in the Companys Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019. These forward-looking statements represent the Companys judgment as of the time of this report. The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: September 30, 2019||By:|
|Laura Shawver, Ph.D.|
|President and Chief Executive Officer|
THOR-707, a Novel Not-alpha IL-2, Promotes All Key Immune System Anti-tumoral Actions of IL-2 Without Eliciting Vascular Leak Syndrome (VLS)
Marcos E. Milla; Jerod L. Ptacin; Lina Ma; Carolina E. Caffaro; Hans R. Aerni; Kristine M. San Jose; Michael J. Pena; Robert W. Herman; Yelena Pavlova; David B. Chen; Taylor Ismaili; Shukuan Li; Jasmine Nguyen; Namit Singh; Laura K. Shawver; Lilia K. Koriazova; Ingrid B. Joseph
Synthorx Inc. Research & Development, La Jolla, CA